Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA considers changes to GLP rules for non-clinical laboratory studies

This article was originally published in RAJ Devices

Executive Summary

The US Food and Drug Administration is considering amendments to good laboratory practice (GLP) regulations for sites that conduct non-clinical studies to support applications for research or marketing permits of drugs, medical devices and other regulated products1.

You may also be interested in...



How To Manage Pharmacovigilance Inspections In A Globalized World

As companies undergo pharmacovigilance inspections from a growing multitude of regulatory authorities from around the globe, a senior pharmaceutical industry executive discusses how her company has been handling this complex and challenging task.

Inspection Interviews: Dutch Official Addresses Frustrations And Misconceptions

While inspection interviews can be stressful for drug firms, a Dutch pharmacovigilance inspector reassures companies that any responses made during the process cannot undo any good work they have already done. And they can also correct any wrong answers later on.

How Saudi Arabia Differs From The EU On Pharmacovigilance Inspections

The Saudi Food & Drug Authority looks at the number of individual case safety reports (ICSRs) submitted by a company, among other risk-based factors, when drawing up its list for routine pharmacovigilance inspections.

UsernamePublicRestriction

Register

LL1133145

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel